News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Dyax Corp. Posts Q4 Profit; Says Can Fund Operation Through 2009
February 25, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Feb 25 (Reuters) - Biotechnology company Dyax Corp posted a quarterly profit on deferred revenue and said it had resources to fund operations through 2009.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Mergers & acquisitions
Amgen Makes up to $840M Cancer Play With Dark Blue Takeover
January 7, 2026
·
1 min read
·
Tristan Manalac
Manufacturing
2026: Putting the Reindustrialization Mandate Into Practice
January 6, 2026
·
4 min read
·
Nick Paul Taylor
Weight Loss
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones
January 5, 2026
·
3 min read
·
Annalee Armstrong
Obesity
Novo Unveils Oral Wegovy in the US, With Out-of-Pocket Prices at $149 Per Month
January 5, 2026
·
2 min read
·
Dan Samorodnitsky
